Zoll Medical (NSDQ:ZOLL) got some love from Wall Street today, after beating analysts’ 1st-quarter estimates with double-digit sales growth and a 71% earnings spike.
Shares were up 7.1% to $69.01 this morning as of about 10:30, after a $64.40 close last night.
The Chelmsford, Mass.-based resuscitation device maker beat The Street’s earnings-per-share forecast of 25 cents, posting profits of $6.7 million, or 29 cents per diluted share, on sales of $133.7 million for the 3 months ended Jan. 2.
The company cited strong sales growth for its LifeVest wearable defibrillator as well as for its temperature management portfolio.
LifeVest sales increased 18% in North America to $68.3 million in the latest quarter. Temperature management device sales rose 27% to $7.5 million.